If you have been reading about Dinucleotide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-21. Numbers and descriptions here follow the published literature rather than marketing material.
Research on NAD+ often examines changes with age, diet, exercise, and disease states, but causal relationships are difficult to establish. Some studies measure NAD+ levels, while others assess enzyme activity or downstream markers. In the literature, terms such as "NAD+ decline" and "NAD+ boosting" appear in both scientific and commercial contexts, sometimes without precise definitions. Whether changes in measured NAD+ directly produce health effects remains an open question. Results from cells, animals, and humans cannot be assumed to translate directly.
Measuring NAD+ in biological samples requires rapid processing because the compound can degrade or interconvert after collection. Common approaches include enzymatic cycling assays, high-performance liquid chromatography, and mass spectrometry. Each method has different sensitivity, specificity, and susceptibility to interference from related nucleotides. Sample type matters: cultured cells, animal tissues, and human blood present distinct challenges. Reported values can vary widely across laboratories because of differences in extraction, normalization, and analytical platform. Standardization remains an open issue in the field.
Quantification of NAD+ in biological samples typically uses liquid chromatography coupled to mass spectrometry. Enzymatic cycling assays offer higher throughput and rely on NAD+ dependent dehydrogenases to amplify signal. Both approaches require careful sample quenching because NAD+ can be rapidly consumed or converted after collection. Acidic extraction is common for NAD+, while alkaline conditions favor NADH in some protocols. Isotopically labeled internal standards help correct for losses during extraction and ionization.
Commercial NAD+ is available at research grade, often with purity specifications determined by high-performance liquid chromatography. Certificates of analysis may report water content, residual solvents, and counterion identity. Identity can be confirmed by ultraviolet absorbance near 260 nm, mass spectrometry, or enzymatic activity. Because different salt forms and hydration states exist, researchers should verify that the product matches the intended molecular form. Lot-to-lot variation in purity can affect quantitative assays and should be documented.
Solid NAD+ is usually supplied as a white to off-white powder or lyophilized preparation. It is hygroscopic and should be kept desiccated at low temperature, commonly -20 °C or below for long-term storage. Aqueous solutions are less stable than dry material and are often prepared fresh or stored frozen in aliquots. Light exposure and repeated freeze-thaw cycles can promote degradation, so amber containers and single-use aliquots are preferred. Buffered solutions near neutral pH are generally less stable than acidic or frozen preparations.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical solid form; varies with purity |
| Storage temperature | -20 °C or lower | Common for long-term dry storage |
| Solubility class | Water-soluble | Also dissolves in aqueous buffers |
| Typical analytical method | HPLC or LC-MS | Used for quantification in complex samples |
| UV absorbance maximum | About 259 nm | In neutral aqueous solution |
In humans, NAD+ can be synthesized from nicotinic acid, nicotinamide, nicotinamide riboside, and tryptophan through overlapping pathways. The salvage pathway recycles nicotinamide back to NAD+ and is often considered a major route in many tissues. Dietary precursors and intracellular recycling both contribute to the pool, but the quantitative importance of each source remains an active research question. NAD+ levels are not uniform across organs or cell compartments. Measurements in blood do not necessarily reflect concentrations inside tissues.
NAD+ is a dinucleotide composed of nicotinamide, ribose, and adenine linked by phosphate groups. Its full name is nicotinamide adenine dinucleotide, with "+" denoting the oxidized form. The molecule acts as a coenzyme in redox reactions, cycling between NAD+ and NADH. In cells, it participates in electron transfer during glycolysis, the citric acid cycle, and oxidative phosphorylation. It is distinct from NADP+, which carries an additional phosphate group and supports different biosynthetic reactions.
Beyond electron transfer, NAD+ serves as a substrate for enzymes that cleave the molecule and transfer ADP-ribose units. Sirtuins, poly(ADP-ribose) polymerases, and CD38 consume NAD+ in regulatory reactions. These activities link NAD+ availability to DNA repair, chromatin modification, calcium signaling, and metabolic stress responses. Because consumption can exceed biosynthesis under some conditions, cellular NAD+ levels are dynamic rather than fixed. Enzyme affinity and local synthesis also influence how much NAD+ is available for signaling.
NAD+ is a dinucleotide composed of adenine, ribose, and nicotinamide moieties linked by phosphate groups. Its oxidized form carries a positive charge on the nicotinamide ring, which enables reversible hydride transfer. The molecule functions as a coenzyme in oxidoreductase reactions rather than as a dietary vitamin in its intact form. Cells maintain separate pools in cytoplasm, mitochondria, and nucleus. This compartmentalization allows distinct redox environments while preserving a shared chemical identity.
Beyond redox chemistry, NAD+ is consumed as a substrate by enzymes that transfer ADP-ribose or remove acetyl groups. Sirtuins use NAD+ in deacylation reactions, poly(ADP-ribose) polymerases use it in DNA damage responses, and CD38 hydrolases convert it to signaling metabolites. Because these enzymes compete for the same pool, changes in NAD+ availability can influence multiple cellular processes. The relative contribution of each consumption route differs by cell type and condition, and precise quantitative links remain an active area of study.
Research on NAD+ spans biochemistry, aging biology, and metabolism. Studies often examine how NAD+ levels change with age, diet, exercise, or disease states, and whether precursor supplementation alters those levels. Findings in animal models do not automatically translate to humans, and measurement methods vary across studies. Questions about tissue-specific effects, long-term consequences, and causal relationships remain open. NAD+ itself is not established as a single therapeutic agent with a broad clinical role.
Nicotinamide adenine dinucleotide, abbreviated NAD+, is a dinucleotide composed of two nucleotides joined by phosphate groups. One nucleotide contains adenine; the other contains nicotinamide. The molecule exists in oxidized (NAD+) and reduced (NADH) forms, and the reversible hydride transfer between them underlies many metabolic oxidation-reduction reactions. In cells, NAD+ serves as an electron acceptor in pathways such as glycolysis, the citric acid cycle, and oxidative phosphorylation. Its concentration and redox ratio vary by compartment, tissue, and metabolic state.
==== Freezing most programs for 90 days ==== DOGE dismantled most of USAID, which had been a 10,000-person agency originally tasked to carry-out humanitarian projects. USAID's critics maintained that many of the projects were in fact not all that humanitarian and/or much of the money was not well spent. In January 2025, the administration issued a 90-day stop-work order worldwide, Stop work interrupted about 30 clinical trials, and interrupted projects such as emergency medical care for displaced Palestinians and Yemenis, aid for war refugees on the Sudan-Chad border, and electricity for Ukrainian refugees. The HIV Modeling Consortium estimated the death toll from HIV in sub-Saharan Africa at approximately 15,000 adults and 1,600 children in the one month after Trump's January 2025 funding freeze. A key controversy is whether or not waivers are being made and money actually starting to flow again for the most essential programs. For example, the Associated Press reported on February 19, that waivers for PEPFAR, the program that has saved 26 million lives from AIDS, were not in force, despite a federal judge having lifted the funding freeze.
Médecins Sans Frontières welcomed the decision, but criticized GSK for failing to include HIV patents in its patent pool and for not including middle-income countries in the initiative. In 2013, GSK licensed its HIV portfolio to the Medicines Patent Pool for use in children, and agreed to negotiate a license for dolutegravir, an integrase inhibitor then in clinical development. In 2014, this license was extended to include dolutegravir and adults with HIV. The licenses include countries in which 93 per cent of adults and 99 per cent of children with HIV live. Also in 2013 GSK joined AllTrials, a British campaign to ensure that all clinical trials are registered and the results reported. The company said it would make its past clinical-trial reports available and future ones within a year of the studies' end. GSK has largely had an access strategy, providing medicines at a subsidized price to lower and middle income markets including Africa under the former CEO Andrew Witty. In 2017, its new CEO, Emma Walmsley, shifted away from this with GSK exiting all Sub-Saharan African markets and there being no plans to provide its newer expensive oncology and genetics pipeline to this population.
=== CHIP, Medicaid, and Medicare Coverage === In April 2025, the Trump Administration declined to finalize a Biden Administration proposal that would have required Medicare, Medicaid, and the Children's Health Insurance Program (CHIP) to broadly cover GLP-1 drugs for weight loss. In November 2025, the Trump Administration announced TrumpRx to lower the price of GLP-1 drugs to $245 per month for people covered by Medicare. Coverage for people with obesity and at least one comorbidity (elevated LDL-cholesterol, high blood pressure and/or MASLD) may be implemented as early as April 2026. The cost will be significantly higher because most insurance companies do not cover it in their formulary. Before this change, most people covered by Medicaid and CHIP paid $3 a month, the same as for brand-name medications. Starting in July 2026, eligible Medicare beneficiaries will gain access to certain weight-loss medications for $50 a month through a temporary initiative called the Medicare GLP-1 Bridge program. This pilot is designed to create a more affordable pathway for people who need these treatments while broader, long-term coverage options are being finalized.
The TNXB gene has an associated pseudogene, TNXA. Both TNXA and TNXB genes are located within the RCCX cluster, which consists of a series of modules with genes close to each other: winged helix repair factor 1 (WHR1), complement 4 (C4), steroid 21-hydroxylase (CYP21), and tenascin-X (TNX). In a monomodular structure of the RCCX cluster, all of the genes are functional, i.e. protein-coding, but if there are two or more modules within the cluster, there is only one copy of each functional gene rest being non-coding pseudogenes with the exception of the C4 gene which always has active copies. For example, in a bimodular configuration most common among Europeans, the cluster consists of the following genes: WHR1-C4A-CYP21A1P-TNXA-STK19B-C4B-CYP21A2-TNXB. As such, TNXA is a duplicated copy of TNXB, but is incomplete, therefore, TNXA a pseudogene that is transcribed but does not encode a protein. The presence of the pseudogene is a consequence of MHC class III locus duplication during evolution. Strong 3' homology between TNXB and TNXA can provoke genetic recombination between the two loci, thus leading to the apparition of TNXA/TNXB chimera.
Sources: en.wikipedia.org
Before pregnancy, people with EDS may be recommended to have genetic counseling and to familiarize themselves with the risks pregnancy poses. Children with EDS should be given information about the disorder so they can understand why they should avoid contact sports and other physically stressful activities. Children should be taught that they should not demonstrate the unusual positions they can maintain due to loose joints, as this may cause early degeneration of the joints. Emotional support, along with behavioral and psychological therapy, can be useful. Support groups can be immensely helpful for people dealing with major lifestyle changes and poor health. Family members, teachers, and friends should be informed about EDS so they can accept and assist the child.
Uranium-234 (234U or U-234) is an isotope of uranium. In natural uranium and in uranium ore, 234U occurs as an indirect decay product of uranium-238, but it makes up only 0.0055% (55 parts per million, or 1/18,000) of the raw uranium because its half-life of just 245,500 years is only about 1/18,000 as long as that of 238U. Thus the ratio of 234U to 238U in a natural sample is equivalent to the ratio of their half-lives. The primary path of production of 234U via nuclear decay is as follows: uranium-238 nuclei emit an alpha particle to become thorium-234. Next, with a short half-life, 234Th nuclei emit a beta particle to become protactinium-234 (234Pa or more usually the isomer 234mPa). Finally, 234Pa or 234mPa nuclei emit another beta particle to become 234U nuclei. Uranium-234 nuclei decay by alpha emission to thorium-230, except for the tiny fraction (here less than 2 per trillion) of nuclei that undergo spontaneous fission. Disequilibrium between the two uranium isotopes does occur in nature when the uranium is dissolved, and is restored again with the half-life of uranium-234; this is the basis of uranium–uranium dating and must be accounted for in the more common uranium–thorium dating. Extraction of the rather small amount of 234U from natural uranium would be possible using isotope separation, similar to that used for regular uranium-enrichment.
== Mechanism of action == Ranirestat is aldose reductase inhibitor that acts by reducing sorbitol accumulation in cells. Aldose reductase is an enzyme that catalyzes one of the steps in sorbitol (polyol) pathway which is responsible for formation of fructose from glucose. Aldose reductase activity is increased, parallel to glucose blood levels, in tissues that are not insulin sensitive, including lenses, peripheral nerves and renal glomeruli. Sorbitol does not diffuse through cell membranes easily and therefore accumulates in these tissues, causing osmotic damage, leading to retinopathy and neuropathy.
=== Abuse of LGBTQ+ people === According to Amnesty International on 9 February 2024, two Houthi-run courts in Yemen sentenced 48 individuals either to death, flogging, or prison over charges related to same-sex conduct in the past month.
Regardless of the initial method of preparation, multiple donations may be combined into one container using a sterile connection device to manufacture a single product with the desired therapeutic dose. Apheresis platelets are collected using a mechanical device that draws blood from the donor and centrifuges the collected blood to separate out the platelets and other components to be collected. The remaining blood is returned to the donor. The advantage to this method is that a single donation provides at least one therapeutic dose, as opposed to the multiple donations for whole-blood platelets. This means that a recipient is exposed to fewer donors and has less risk of transfusion-transmitted disease and other complications. Sometimes a person such as a cancer patient who requires routine transfusions of platelets receives repeated donations from a specific donor to minimize risk. Pathogen reduction of platelets using for example, riboflavin and UV light treatments can reduce the infectious load of pathogens contained in donated blood products. Another photochemical treatment process utilizing amotosalen and UVA light has been developed for the inactivation of viruses, bacteria, parasites, and leukocytes. In addition, apheresis platelets tend to contain fewer contaminating red blood cells because the collection method is more efficient than "soft spin" centrifugation.
Sources: en.wikipedia.org
Researchers often use enzymatic cycling assays, liquid chromatography, or mass spectrometry. The choice depends on sample size, sensitivity needs, and available equipment. Because NAD+ can degrade quickly, rapid extraction and careful handling are important.
Differences can arise from sample type, extraction method, normalization strategy, and analytical platform. Time of day, diet, and physiological state may also matter. These factors make direct comparisons across studies difficult.
NAD+ is generally more stable when stored dry and cold, and it can degrade in aqueous solutions over time. Heat, light, and alkaline conditions can accelerate loss. Laboratory protocols therefore often recommend frozen storage and protection from light.
Aqueous NAD+ solutions are best kept frozen in aliquots and protected from light. Repeated freezing and thawing is avoided because it can accelerate breakdown. Dry powder stored desiccated at -20 °C or lower typically remains stable for longer periods.